Voluntis, producers of therapeutic companion software to help people manage their chronic diseases, has received FDA 510(k) clearance and the CE Mark for Insulia, a digital way of helping patients with type 2 diabetes manage the disease.

"To make a meaningful impact on patients' daily lives as well as clinical outcomes, we need to use intelligent digital solutions that go beyond data sharing between patients and clinicians. This is what Research Center for the Intensification of Diabetes Treatment (CERITD) and Voluntis have been working on together for more than 10 years, designing and evaluating software that provides automated recommendations and clinical decision support to take diabetes care management to the next level," said Guillaume Charpentier, MD, president of CERITD.

For the 30 million Americans with diabetes, the main treatment is basal insulin, but more than half of patients do not meet the requirements for glycemic control. As a way to improve medication adherence, Insulia Diabetes Management Companion has incorporated teaching, adherence and quality into one device.

Insulia Diabetes Management Companion, which can be obtained through a prescription, provides patients with recommendations on insulin dosage, as well as educational resources sent through a messaging feature. The data is then sent to the patient’s physicians where they can personalize care and discuss the best treatment options.

Using an adjustment algorithm, the app is capable of giving automated insulin dosing recommendations. This information is readily available to patients and physicians through smartphones and tablets. With tailored notifications and goal setting, Insulia keeps patients on track in managing diabetes.

"Type 2 diabetes is a complex condition, especially for people who have transitioned to insulin therapy. Indeed, self-monitoring blood glucose and self-managing insulin doses is cumbersome and challenging for a majority of patients. As a result, harnessing new and reliable technologies to support patients in safely managing insulin dosing while keeping in touch with healthcare team could be well received by provider and patient communities," said Ananda Basu, MD, endocrinologist at the Mayo Clinic in Rochester, Minnesota.